AbbVie News Center - News
Oct 31, 2024 · AbbVie to Acquire Aliada Therapeutics, Strengthening Focus in Alzheimer's Disease and Neuroscience Pipeline. October 24, 2024. AbbVie and Gedeon Richter Announce New Collaboration for the Discovery and Development of Novel Targets for Neuropsychiatric Conditions. October 18, 2024.
AbbVie to Acquire ImmunoGen, including its Flagship Cancer
Nov 30, 2023 · The acquisition accelerates AbbVie's commercial and clinical presence in the solid tumor space. Additionally, ImmunoGen's follow-on pipeline of promising next-generation ADCs further complements AbbVie's ADC platform and existing programs.
AbbVie to Acquire Cerevel Therapeutics in Transformative ... - News
Dec 6, 2023 · Cerevel's clinical-stage pipeline complements AbbVie's current on-market portfolio and emerging neuroscience pipeline. Emraclidine has the potential to transform the standard of care in schizophrenia and other psychiatric conditions. Transaction valued at $45.00 per share in cash, for a total equity value of approximately $8.7 billion.
AbbVie Completes Acquisition of ImmunoGen - Feb 12, 2024
Feb 12, 2024 · AbbVie expects its acquisition of ImmunoGen to be accretive to AbbVie's diluted EPS beginning in 2027 and significantly accretive over the long-term. Full-Year 2024 Outlook. AbbVie is reaffirming its previously issued 2024 full-year …
AbbVie to Acquire Landos Biopharma, Further Strengthening its
Mar 25, 2024 · NORTH CHICAGO, Ill. and NEW YORK, March 25, 2024 / PRNewswire / -- AbbVie Inc. (NYSE: ABBV) ("AbbVie") and Landos Biopharma, Inc. (NASDAQ: LABP) ("Landos") today announced a definitive agreement under which AbbVie will acquire Landos, a clinical stage biopharmaceutical company focused on the development of novel, oral therapeutics for patients ...
AbbVie Announces Positive Topline Results from Phase 2 ... - News
NORTH CHICAGO, Ill., Nov. 29, 2023 / PRNewswire / -- AbbVie (NYSE: ABBV) announced today topline results from the single-arm Phase 2 LUMINOSITY trial evaluating telisotuzumab-vedotin (Teliso-V) in patients with c-Met protein overexpression, epidermal growth factor receptor (EGFR) wild type, advanced/metastatic nonsquamous non-small cell lung ...
AbbVie Reports Full-Year and Fourth-Quarter 2023 Financial Results
Feb 2, 2024 · Reports Fourth-Quarter Diluted EPS of $0.46 on a GAAP Basis, a Decrease of 66.7 Percent; Adjusted Diluted EPS of $2.79, a Decrease of 22.5 Percent; These Results Include an Unfavorable Impact of $0.15 Per Share Related to Fourth-Quarter 2023 Acquired IPR&D and Milestones Expense.
AbbVie Completes Acquisition of Cerevel Therapeutics
Aug 1, 2024 · AbbVie Completes Acquisition of Cerevel Therapeutics. Cerevel's clinical-stage assets complement AbbVie's emerging neuroscience pipeline and leading on-market brands in psychiatry, migraine and Parkinson's disease.
AbbVie Announces Appointment of Robert A. Michael as Chief …
Feb 20, 2024 · Richard A. Gonzalez to retire as AbbVie CEO to become Executive Chairman. Transition will occur on July 1, 2024. NORTH CHICAGO, Ill., Feb. 20, 2024 / PRNewswire / -- AbbVie (NYSE: ABBV) today announced that its board of directors has unanimously selected Robert A. Michael, AbbVie's current president and chief operating officer, to succeed ...
AbbVie Completes Transformative Acquisition of Allergan
May 8, 2020 · AbbVie Completes Transformative Acquisition of Allergan. - Creates biopharmaceutical company with leadership positions in key therapeutic areas: Immunology, Hematologic Oncology, Neuroscience, and Allergan Aesthetics. - Robust portfolio of on-market and pipeline assets well-positioned for sustainable long-term growth.